Drug intelligence / Profile preview

68Ga-DOTA-CCK-FS

Development stage: Preclinical
Lead developer: Peking Union Medical College Hospital
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration: Intravenous

Overview

**68Ga-DOTA-CCK-FS** is an investigational gallium-68 PET radiopharmaceutical designed to image tumors expressing the cholecystokinin-2 receptor. The tracer combines the positron-emitting radionuclide gallium-68 with a DOTA-chelated CCK-2 receptor-targeting peptide ligand, enabling PET/CT visualization of receptor-positive lesions. It is being evaluated in a recruiting clinical imaging study for medullary thyroid carcinoma and other cholecystokinin-2 receptor-positive malignancies, with comparison against standard PET tracers including fluorodeoxyglucose or gallium-68 DOTATATE. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07138716))

Other names: 68Ga-DOTA-CCK-FS

Targets

CCK2R (Cholecystokinin 2 Receptor)

Beyond the preview

Go deeper on 68Ga-DOTA-CCK-FS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 68Ga-DOTA-CCK-FS.

Explore the full profile